JMJD1C — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4564955	0.45	3/20
SCHEMBL27845531	0.51	2/20
SCHEMBL3645046	0.44	2/20
SCHEMBL3645047	0.44	2/20
SCHEMBL18666063	0.41	2/20
SCHEMBL18943862	1.00	1/20
SCHEMBL22186826	0.69	1/20
SCHEMBL22186399	0.65	1/20
SCHEMBL22186831	0.63	1/20
SCHEMBL670431	0.62	1/20
SCHEMBL29502663	0.62	1/20
SCHEMBL2714790	0.61	1/20
SCHEMBL23954513	0.59	1/20
SCHEMBL18266721	0.59	1/20
SCHEMBL4218788	0.58	1/20
SCHEMBL1457909	0.58	1/20
SCHEMBL18266119	0.58	1/20
SCHEMBL22186405	0.58	1/20
SCHEMBL25310394	0.57	1/20
SCHEMBL25311281	0.57	1/20

Clinical trials — most relevant to JMJD1C by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors	PHASE2	RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation	PHASE2	UNKNOWN
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer	PHASE1/PHASE2	RECRUITING
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors	PHASE1	RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies	nan	UNKNOWN
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Mechanisms of Immune Deficiency	nan	UNKNOWN
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer	nan	UNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED
A Study of Multilocus Methylation Abnormalities in Subjects With Imprinting Disorders	nan	NOT_YET_RECRUITING
The Danish TURNER Cryopreservation Study	nan	RECRUITING
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia	nan	UNKNOWN
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System	nan	UNKNOWN
The Crosstalk Between the Epigenome and Mitochondria in SCI	nan	NOT_YET_RECRUITING
Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)	nan	COMPLETED
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
Familial Investigations of Childhood Cancer Predisposition	nan	RECRUITING
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a JMJD1C binder may also engage these)

Protein	Name	Similarity
Q69ZK6	—	1.000	Q69ZK6 →
Q9JJN2	—	0.993	Q9JJN2 →
P40645	—	0.993	P40645 →
Q9BTA9	—	0.992	Q9BTA9 →
O73590	—	0.992	O73590 →
Q8R5I7	—	0.992	Q8R5I7 →
Q2KHR2	—	0.992	Q2KHR2 →
Q8BZ32	—	0.991	Q8BZ32 →
Q568E2	—	0.991	Q568E2 →
O35738	—	0.991	O35738 →
A6QP06	—	0.991	A6QP06 →
Q9ULH7	—	0.991	Q9ULH7 →
Q90YL3	—	0.991	Q90YL3 →
D4AEC2	—	0.991	D4AEC2 →
Q8C0C0	—	0.991	Q8C0C0 →
P97868	—	0.991	P97868 →
Q5RCU4	—	0.990	Q5RCU4 →
Q27IV2	—	0.990	Q27IV2 →
A6H5Y1	—	0.990	A6H5Y1 →
Q66J90	—	0.990	Q66J90 →
P40647	—	0.990	P40647 →
Q6ZN30	—	0.990	Q6ZN30 →
Q7Z353	—	0.990	Q7Z353 →
P35710	—	0.990	P35710 →
Q16649	—	0.990	Q16649 →
P35711	—	0.990	P35711 →
A2AHC3	—	0.989	A2AHC3 →
A0A1L8HFX9	—	0.989	A0A1L8HFX9 →
B3DJM5	—	0.989	B3DJM5 →
F1M8W4	—	0.989	F1M8W4 →